Date: 2014-09-16
Type of information: Collaboration agreement
Compound:
Company: Pharnext (France) Hereditary Neuropathy Foundation (USA - NY)
Therapeutic area: Rare diseases - Genetic diseases - Neurological diseases
Type agreement: collaboration
Action mechanism:
Disease: Charcot-Marie-Tooth disease
Details:
- • On September 16, 2014, the French biopharmaceutical company Pharnext and the Hereditary Neuropathy Foundation (HNF) announced an agreement to collaborate on programs to increase the awareness around Charcot-Marie-Tooth (CMT) disease and support the development of a stronger CMT patient and research community. Pharnext will provide financial support to several HNF\'s initiatives including:
- - Enhanced design and development of a specific section in the HNF website featuring HNF newsletters, materials and latest news on CMT research (http://www.hnf-cure.org/newsletter-cmt-update) ;
- - Implementation of a video campaign during the CMT Awareness month in September 2014 in the US ;
- - Improvement of HNF's CMT Support Community hosted on Inspire (http://www.inspire.com/groups/charcot-marie-tooth-cmt)
- - Expansion of the Global Registry for Inherited Neuropathies (GRIN) co-founded by HNF and Hannah\'s Hope Fund (HHF) for Giant Axonal Neuropathy (GAN) (www.neuropathyreg.org)
- GRIN has been developed by HNF and HHF to collect clinical and genetic information on patients diagnosed with the various forms of hereditary neuropathies such as CMT and GAN in order to advance therapies development for these debilitating disorders. Expanding GRIN further will allow researchers working on new therapies for hereditary neuropathies to access an invaluable source of data to move forward their research.
- Pharnext is an advanced clinical stage biopharmaceutical company discovering and developing new therapeutics that target multiple key disease pathways for orphan and common neurological diseases including Charcot-Marie-Tooth disease, Alzheimer\'s disease, amyotrophic lateral sclerosis and Parkinson\'s disease. These new therapeutics consist of low dose combinations of repositioned drugs selected using Pharnext\'s proprietary network pharmacology approach. The company\'s first two lead programs are PXT-3003 for the treatment of Charcot Marie Tooth type 1A (phase 2 completed) and PXT-864 for Alzheimer\'s disease (phase 2 ongoing) and other neurology indications.
Financial terms:
Latest news:
Is general: Yes
